Treatment-related upper-limb morbidity one year after sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND) for stage I or II breast cancer J
western-blot. Cell cycle and apoptotic activity were measured by flow cytometry. RESULTS: hML1 expression was restored in deficient lines by hMLH1-wild type transfection. RNAi inhibited expression ofpl2DOC-1 mRNA and protein expression in p 12DOC-1 expressing lines and in multile lines in which pl2DOC-1 was overexpressed. In all construct settings mRNA and protein levels ofpl2DOC-1 were not affected by pSUPER-RNAi mutant type negative control vectors. Among constitutive p 12DOC-1 expressing lines (SW480 and HCT-29) RNAi pl2DOC-1 increased S-phase cell population and decreased percentages of apoptotic cells. Conversely, cell cycle arrest and induction of apoptosis was observed in lines in which over expression ofpl2DPC-1 was induced. CONCLUSION: These results demonstrate that our novel RNAi mediated modulation ofp 12DOC-expression influenced cell cycle kinetics and apoptotic behaviour consistent with results reported in our prior studies. These RNAi based results directly support our hypothesis that increased S-phase and decreased apoptosis observed in MSI+ human CRC cell lines is mediated by decreased pl2DOC-1 expression. We conclude pl2DOC-1 is an important growth regulator in colon epithelial cells, pl2DOC-1 expresion modulation may provide a novel molecular mechanism for CRC prevention and therapy in the future.
infusion from post-operative day 2 for 4weeks and, then eight times bi-weekly intra-arterial 5FU (1250mg/day) infusion at outpatient clinic. Disease free survival rate for hepatic recurrence and cumulative survival rates were compared between the both group by intention to teat method. Results: There were four stage III and nine stage IV patients in intra-arterial infusion group and were five stage III and nine stage IV patients in the control group. Twelve patients were completed with intra-arterial infusion without any intensive adverse effects, while one patients was not completed due to gastrointestinal toxicity. One and three-years disease free survival rate for hepatic recurrence were 91% and 91% in the intra-arterial infusion group, while these were 52% and 33% in the control group (P<0.01). One and three-years cumulative survival rates were 92% and 63% in the intra-arterial infusion group, while were 69% and 23% in the control group (P<0.05). One and three-years local recurrence rate were 17% and 51% in the intra-arterial infusion group, and 15% and 57% in the control group, respectively. Conclusion: Post-operative intra-arterial infusion chmotherapy seems to improve the outocome of patients who underwent the curative pancreatoduodenectomy for adenocarcinoma of the pancreas due to prevention of hepatic recurrence.
Introduction The ER is emerging as a realistic new clinical target for estrogen-induced inhibition of cell growth and apoptosis in breast cancer. ER positive cells that are completely refractory to either estrogen withdrawal (aromatase inhibition) or tamoxifen and raloxifene rapidly stop growing and die, in vivo or in vitro, when exposed to physiologic concentrations of estradiol (E2,1nM). The goal of this project is to reintroduce cDNAs for wild type and mutant ERs into ER negative breast cancer cells to study the mechanism of estrogen regulated growth. Methods ER negative MDA-MB-231 breast cancer cells were stably transfected with cDNA for wild type ER, K303R ER, a reportedly supersensitive mutant of the ER and E203A/G204A ER, a mutant that prevents DNA binding and gene transcription. Three clones were selected to evaluate growth responses to increasing concentrations of E2 and apoptosis (Annexin V) compared to etoposide (50microM). Results Increasing concentrations of E2 (0.1 to 100nM) caused a complete decrease in cell replication of all transfectants and E2 did not affect the growth of ER negative MDA-MB-231 cells. Unlike etoposide, ER transfectants did not induce apoptosis even up to six days orE2 exposure. There was no significant difference in the efficacy of each ER mutant compared to wild type ER. Conclusions We found no evidence that the apparently supersensitive ER mutant K303R was any different than the wild type ER. Most importantly, the DNA binding mutant caused equivalent suppression of cell replication compared to wild type ER, supplying a nongenomic method of action for ER. None of the ER transfectants induced apoptosis suggesting that all survival mechanisms in the MDA-MB-231 cells need to be neutralized to shift the cellular equilibrium from cellular stasis and quiescence to a full apoptotic response. Supported by the Avon Foundation and SPORE in breast cancer P50 CA89018-04. Introduction: Hepatic recurrence is a major cause of treatment failure after curative pancreatoduodenectomy for patients with adenocarcinoma of the pancrease. Effective adjuvant therapy after the curative resection should be established. Methods: A prospective randomized clinical trial of postoperative intraarterial infusion therapy via hepatic artery was performed. Twenty seven patients were allocated randomly at operation after curative resection to an intra-arterial infusion group (13 patients) who underwent catheterization in the hepatic artery at surgery or a control(surgery alone) group (i4 patients). Patients in the intra-arterial infusion group received continuous intm-arterial 5FU (125mg/day) Introduction The goals of the sentinel lymph node biopsy (SLNB) in breast cancer treatment are to improve axillary staging and reduce unnecessary axillary lymph node dissections (ALND), thereby reducing treatment-related upperlimb morbidity. In a prospective study, upper-limb morbidity was assessed before and one year after SLNB and/or ALND. Methods 204 patients (pts) with stage I/II breast cancer, mean age 55.6 years (sd: 11.6) entered the study and 189 pts could be evaluated after one year. 85 pts underwent only SLNB (31%) and 131 pts underwent a level I-II ALND (69%). Assessment, pre-operative (tO) and one year postoperative (t 1), included shoulder range of motion, muscle strength, grip strength, pain, upper/foreaIm circumference, shoulder disability and activities of daily life (ADL). Results Considerable treatment related upper-limb morbidity was observed. Significant (p<0.05) changes were found in all assessments except strength of elbow flexors. Significant difference in change between the SLNB and the ALND group was found for range of motion in forward flexion, abduction and abduction / external rotation, grip strength and strength of shoulder abductors, circumference of upper and forearm and in perceived shoulder disability.(see Table) Multivariate linear regression analysis showed that ALND could significant predicts changes of range of motion in forward flexion, abduction, strength shoulder abductors, grip strength and circumference of upper/forearm. Conclusion After one year follow up there is significant less upper-limb morbidity after SLNB compared to ALND in the treatment of breast cancer. ALND is in the majority of the assessment variables the significant predictor for upper-limb morbidity.
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Introduction:
More efficient clinical management of early-stage melanoma patients can be achieved through the accurate assessment of local recurrence and disease progression. Tumor progression is a dynamic sequence of events that involves specific protein changes. We hypothesized that Surface Enhanced Laser Desorption/Ionization (SELDI) mass spectrometric analysis ofsera from patients with AJCC stage I and II melanoma with negative loco-regional lymph nodes could identify potential melanoma-associated protein biomarkers of disease recurrence and progression. Methods: Serum specimens were obtained from 49 patients who developed recurrence (n=25) or remained free of recurrence (n=24) after complete resection of primary melanoma (AJCC stage I and II). All patients had a follow-up greater than 5 yrs. Serum proteins were denatured and applied onto two protein chip chemistry surfaces (metal-binding, IMAC3-Cu; weak cationic WCX2). SELDI Protein Chip mass spectrometry was then performed. SELDI data were analyzed, protein peak clustering and classification were performed and the decision tree algorithm was employed to classify the dataset. Results: Statistically significant differences (p<.05) in multiple protein peaks ranging from 2.8kDa to 50kDa were identified between patients with recurrence and without recurrence, and the expression pattern differences of eight proteins were utilized to generate the discriminating classification tree. The biomarkers were expressed with a high degree of reproducibility. In this early characterization study, melanoma recurrence was predicted with a sensitivity of 69% (17/25) and specificity of 65% (15/24). Conclusion: This pilot study revealed eight differentially expressed proteins that accurately identified patients who developed recurrence after curative resection of primary melanoma. These may become useful as markers of local recurrence and disease progression and could lead toward new serum screening approaches for melanoma upon validation. Additional studies are underway.
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Resection of progressive or residual tumor after treatment with imatinib for advanced GI stromal tumors P. Hohenberger, 1. U. Schneider, 2 D. Pink, 3 K. Emmerich, 4 C. Kettelhack, l O. Roetschke, 4 R Reichardt. 3 1. Div. Surgery and Surgical Oncology, Charite, Berlin, Germany, " 2. Dept. Pathology, Charite, Berlin, Germany; 3. Dept. Medical Oncology, Charite, Berlin, Germany; Berlin. Introduction: Imatinib effectively induces regression in advanced GI stromal tumors (GIST). Resection of residual tumor masses or of lesions no longer responsive may be considered, however, with unknown prognostic value yet. We evaluated morbidity and outcome of tumor resections in this clinical setting. Patients: Two-hundred and four patients with histologically confirmed, CD-117+ GIST received imatinib at 400mg or 800 mg daily. Response was assessed by MRI/CT and 18FDG-PET. Thirty-nine pts. underwent 56 operations: to resect residual tumor mass representing PR (n=9), for solitary progressive lesions coincident to still responding tumor loci (PDinPR, n = 16), for multilocular tumor progression (PD, . Median duration of imatinib therapy was 46 wks (30-94) in the PR group, 54 wks (39-99) in the PDinPR group, and 34 weeks (19-67) in the PD group. All pts but two continued with imatinib postop. Resection specimens were analysed for viable tumor cells by immunohistochemistry and cell cultures. Results: Operative procedures included hepatectomy in 4 pts., multivisceral resection in 18 pts (bowel, stomach, pancreas, kidney, spleen, diaphragm, pericardium, lung) , peritoneal debulking in 13 pts, and pelvic exenteration (n=4). An R0 resection could be achieved in 8/9 pts in the PR group, in 12/16 pts in the PDinPR group, and in 3/14 pts in the PD group (p<0.001 ). Three pts in the PD group died postop, due to uncontrolled bleeding, sepsis, or kidney failure (overall mortality 7.7%). Histologically, no CR was observed and cell lines could be established from all but one lesions. Median progression-free survival is 30 weeks in the PR group, 27 weeks in the PDinPR group, and 10 weeks in the PD group (p<0.0001). Conclusion: Patients with advanced GIST developing PR under imatinib should be re-evaluated for resection as early as possible. Removal of such tumor remnants is a safe procedure as is resection of solitary progressive lesions with other tumor foci under control. In such a setting, long-term cure is a realistic aim. Surgery for multilocular, progressive GIST is accompanied by significant mortality and requires a very careful selection of patients. Introduction: Compared with CT scan, positron emission tomography (FDG-PET) has been shown to be more accurate in the staging of esophageal cancer (EC) and in the monitoring of tumor response to chemoradiotherapy (CRT). However, there is little published data on the impact of the PET findings on treatment decisions and outcomes. This prospective study evaluated the impact of PET imaging on the management of EC patients. Method: Eighty-nine consecutive patients either had their (1) EC staged and/or (2) tumor response to CRT monitored by FDG-PET prior to possible surgery. Their recorded pre-treatment plan, based on CT and endoscopic ultrasound, was compared with treatment based on incorporation of PET findings. High PET impact was defined when there was a change in treatment intent or change in treatment modality (e.g. surgery to CRT). Survival was analyzed using the Kaplan-Meier product limit method and Cox proportional hazards regression model. Results: (1) In primary staging, PET had a high impact on 31 of 68 patients (46%). In 12 patients therapy was changed from curative to palliative, in 3 therapy was changed from palliative to curative, and in 16 the treatment modality was changed but not the treatment intent. The post-PET staging was strongly associated with survival (P<0.001) whereas conventional imaging was not (P=0.46). (2)After completion of CRT, 23 of 53 patients (43%) achieved complete metabolic response (CMR) on PET, compared with only 4 cases (8%) where CT showed no residual disease. High PET impact was observed in 18 patients. CMR on PET, facilitating borderline surgical patients to be observed, was strongly predictive of survival (P<0.001) (Figure 1 ). Within the surgical group, those who had negative PET pre-operatively also had better survival than those who had positive PET (P<0.001). Conclusion: The use of FDG-PET for (1) staging and (2) assessment of therapeutic response after CRT of oesophageal cancer significantly and appropriately changed clinical management in more than half (47/89) of patients. PET also provided excellent prognostic stratification when compared with conventional investigations.
